CSIMarket
 
Relay Therapeutics Inc   (RLAY)
Other Ticker:  
 
 
Price: $7.5000 $-0.45 -5.660%
Day's High: $7.91 Week Perf: -19.79 %
Day's Low: $ 7.40 30 Day Perf: -29.71 %
Volume (M): 1,615 52 Wk High: $ 19.23
Volume (M$): $ 12,110 52 Wk Avg: $10.63
Open: $7.91 52 Wk Low: $5.95



 Market Capitalization (Millions $) 917
 Shares Outstanding (Millions) 122
 Employees -
 Revenues (TTM) (Millions $) 26
 Net Income (TTM) (Millions $) -327
 Cash Flow (TTM) (Millions $) -203
 Capital Exp. (TTM) (Millions $) 6

Relay Therapeutics Inc
Relay Therapeutics Inc is a biotechnology company that focuses on developing new treatments for cancer and other diseases. The company uses a combination of computation, experimental biology, and medicinal chemistry to discover and design potential therapies. Their approach involves studying the movement and interaction of proteins within cells to identify targets for drug development. By understanding how proteins behave, Relay Therapeutics aims to create precise and effective therapies that can address the underlying causes of diseases. The company's goal is to deliver breakthrough treatments and improve patients' lives.


   Company Address: 399 Binney Street Cambridge 2139 MA
   Company Phone Number: 370-8837   Stock Exchange / Ticker: NASDAQ RLAY
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Relay Therapeutics Inc

Relay Therapeutics Inc Sees Astonishing 7226.163% Surge in Revenue, Setting Industry Standards



Relay Therapeutics Inc, a leading biotechnology company, has recently reported impressive financial results for the third quarter of 2023. These results, including significant revenue growth and improved earnings per share, are expected to have a positive impact on the company's future. Let's delve deeper into the facts and consider how they may influence Relay Therapeutics Inc moving forward.
1. Stellar Revenue Growth:
During the third quarter of 2023, Relay Therapeutics Inc experienced a remarkable 7226.163% growth in revenue. The company's revenue surged from $0.34 million in the corresponding quarter of the previous fiscal year to $25.20 million. Moreover, the sequential growth also reflects a doubling of revenue by 21078.151% from $0.12 million in the prior quarter. This exceptional revenue growth showcases Relay Therapeutics Inc's ability to leverage its pharmaceutical advancements, placing it ahead of its industry peers, who experienced a 5.96% average growth during the same period.

Relay Therapeutics Inc

Relay Therapeutics Inc's 2023 Q2 Financials Shock Investors: Revenue Plummets Over 67%



Relay Therapeutics Inc, a renowned biotechnology company, recently unveiled its second-quarter financial results for 2023, leaving investors and analysts alarmed. The company reported a drastic decline in revenue and profit margins, further amplifying concerns about its financial stability. This article aims to shed light on the reasons behind Relay Therapeutics' disappointing performance and explore the potential implications for the company's future.
Alarming Financial Figures:
In the second quarter of 2023, Relay Therapeutics Inc experienced a massive decrease in revenue by a staggering -67.397% to a meager $0.12 million compared to the same period the previous year. This decline in revenue is a significant setback for the company and raises serious concerns about its ability to generate sustainable income.

Relay Therapeutics Inc

Relay Therapeutics Inc Faces Challenging First Quarter of 2023 as Financials Take a Hit

Despite the disappointing financial report from Relay Therapeutics Inc (RLAY) for the first quarter of 2023, investors should remain optimistic about the long-term prospects of this innovative biotechnology company.
Yes, it is undeniable that RLAY's revenue took a major hit, plummeting by a staggering 99.188% to just $0.23 million, and net deficit per share also widened to $-0.78 compared to the same period last year. Additionally, earnings per share fell to $-0.44 from the prior reporting season, while revenue doubled relative to the same period last year at 3666.67%. On top of this, RLAY's net deficit for the March 31, 2023, closed time frame, was $-94.239 million, which was significantly higher than the previous year.






 

Relay Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com